$APLT
Applied Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000155837023014406 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.710M $5.293M
YoY Change -24.52% -13.58%
% of Gross Profit
Research & Development $10.79M $11.88M
YoY Change -17.77% -22.82%
% of Gross Profit
Depreciation & Amortization $0.00 $1.000K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $15.50M $17.18M
YoY Change -19.95% -20.19%
Operating Profit -$15.50M -$17.18M
YoY Change -19.95% -20.19%
Interest Expense $392.0K $408.0K
YoY Change 72.69% 267.57%
% of Operating Profit
Other Income/Expense, Net -$26.88M -$12.40M
YoY Change -10639.22% 186.0%
Pretax Income -$42.37M -$29.58M
YoY Change 121.82% 14.39%
Income Tax
% Of Pretax Income
Net Earnings -$42.37M -$29.58M
YoY Change 121.82% 14.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.47 -$0.37
Diluted Earnings Per Share -$0.47 -$0.37
COMMON SHARES
Basic Shares Outstanding 63.12M 57.85M
Diluted Shares Outstanding 90.67M 79.04M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.50M $35.62M
YoY Change -20.85% -47.41%
Cash & Equivalents $37.50M $35.60M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $837.0K $536.0K
YoY Change 38.58% -10.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.49M $42.82M
YoY Change -19.86% -44.31%
LONG-TERM ASSETS
Property, Plant & Equipment $500.0K $628.0K
YoY Change -48.45% -41.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $197.0K
YoY Change 0.5% -1.01%
Total Long-Term Assets $707.0K $825.0K
YoY Change -39.52% -35.55%
TOTAL ASSETS
Total Short-Term Assets $44.49M $42.82M
Total Long-Term Assets $707.0K $825.0K
Total Assets $45.20M $43.65M
YoY Change -20.26% -44.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.005M $4.687M
YoY Change -13.88% -46.07%
Accrued Expenses $12.70M $16.51M
YoY Change -11.46% -5.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $55.50M $47.19M
YoY Change 19.33% -8.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $700.0K $792.0K
YoY Change 30.6% 20.92%
Total Long-Term Liabilities $735.0K $792.0K
YoY Change 37.13% 20.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $55.50M $47.19M
Total Long-Term Liabilities $735.0K $792.0K
Total Liabilities $56.24M $47.98M
YoY Change 19.53% -8.38%
SHAREHOLDERS EQUITY
Retained Earnings -$430.9M -$388.5M
YoY Change 28.86% 23.22%
Common Stock $7.000K $6.000K
YoY Change 40.0% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.04M -$4.334M
YoY Change
Total Liabilities & Shareholders Equity $45.20M $43.65M
YoY Change -20.26% -44.17%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$42.37M -$29.58M
YoY Change 121.82% 14.39%
Depreciation, Depletion And Amortization $0.00 $1.000K
YoY Change 0.0%
Cash From Operating Activities -$14.73M -$16.45M
YoY Change -24.03% -10.59%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.57M 29.15M
YoY Change -1806.49% -4.06%
NET CHANGE
Cash From Operating Activities -14.73M -16.45M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 16.57M 29.15M
Net Change In Cash 1.840M 12.70M
YoY Change -111.99% -27.49%
FREE CASH FLOW
Cash From Operating Activities -$14.73M -$16.45M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001697532
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
CY2023Q2 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38898
dei Entity Registrant Name
EntityRegistrantName
Applied Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3405262
dei Entity Address Address Line1
EntityAddressAddressLine1
545 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1400
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
220-9226
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
APLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63124227
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35616000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16657000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
13923000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7205000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6728000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
42821000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
37308000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
628000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
857000
CY2023Q2 aplt Security Deposit And Leasehold Improvements Net
SecurityDepositAndLeaseholdImprovementsNet
197000
CY2022Q4 aplt Security Deposit And Leasehold Improvements Net
SecurityDepositAndLeaseholdImprovementsNet
198000
CY2023Q2 us-gaap Assets
Assets
43646000
CY2022Q4 us-gaap Assets
Assets
38363000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
486000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
477000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4687000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4534000
CY2023Q2 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16023000
CY2022Q4 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14756000
CY2023Q2 aplt Warrant Liability Current
WarrantLiabilityCurrent
25992000
CY2022Q4 aplt Warrant Liability Current
WarrantLiabilityCurrent
13657000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
47188000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33424000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
170000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
414000
CY2023Q2 aplt Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
622000
CY2022Q4 aplt Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
464000
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
792000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
878000
CY2023Q2 us-gaap Liabilities
Liabilities
47980000
CY2022Q4 us-gaap Liabilities
Liabilities
34302000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62119466
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62119466
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48063358
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48063358
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
384197000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
352828000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
51000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-388537000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-348823000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4334000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4061000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43646000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38363000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10660000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10660000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11883000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15396000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27818000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30426000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5293000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6125000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10876000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14196000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
17176000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
21521000
us-gaap Operating Expenses
OperatingExpenses
38694000
us-gaap Operating Expenses
OperatingExpenses
44622000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17176000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21521000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28034000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44622000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
408000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
111000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
628000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
187000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12804000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4357000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12335000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4357000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
27000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-186000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12401000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4336000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11680000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4356000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29577000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-25857000
us-gaap Net Income Loss
NetIncomeLoss
-39714000
us-gaap Net Income Loss
NetIncomeLoss
-48978000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29577000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29577000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25857000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25857000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39714000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-39714000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48978000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-48978000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79041695
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79041695
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26901069
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26901069
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67762501
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67762501
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26560185
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26560185
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29577000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-25857000
us-gaap Net Income Loss
NetIncomeLoss
-39714000
us-gaap Net Income Loss
NetIncomeLoss
-48978000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
86000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-51000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
113000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
86000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-51000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
113000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29577000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25771000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39765000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48865000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
62539000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2077000
CY2022Q1 aplt Adjustments To Additional Paid In Capital Options Issued In Lieu Of Bonus
AdjustmentsToAdditionalPaidInCapitalOptionsIssuedInLieuOfBonus
441000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23121000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
27000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
41963000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5968000
CY2022Q2 aplt Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
1417000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2231000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-25857000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
86000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25808000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4061000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2055000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10137000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-51000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4072000
CY2023Q2 aplt Stock Issued During Period Value Common Stock Pre Funded Warrants And Common Stock Warrants Sold For Cash
StockIssuedDuringPeriodValueCommonStockPreFundedWarrantsAndCommonStockWarrantsSoldForCash
27450000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1843000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29577000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4334000
us-gaap Profit Loss
ProfitLoss
-39714000
us-gaap Profit Loss
ProfitLoss
-48978000
us-gaap Share Based Compensation
ShareBasedCompensation
3898000
us-gaap Share Based Compensation
ShareBasedCompensation
4308000
aplt Options Issued In Lieu Of Bonus
OptionsIssuedInLieuOfBonus
441000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
1334000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
2024000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
229000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
217000
aplt Amortization Of Leasehold Improvements
AmortizationOfLeaseholdImprovements
1000
aplt Amortization Of Leasehold Improvements
AmortizationOfLeaseholdImprovements
1000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-235000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-216000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12335000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4357000
aplt Increase Decrease In Financed Insurance Premium
IncreaseDecreaseInFinancedInsurancePremium
1546000
aplt Increase Decrease In Financed Insurance Premium
IncreaseDecreaseInFinancedInsurancePremium
3105000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
265000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
524000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
153000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-770000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
210000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-565000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
158000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23442000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42810000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
14987000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
4944000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8928000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
30041000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13872000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15054000
aplt Proceeds From Issuance Of Shares And Pre Funded Warrants
ProceedsFromIssuanceOfSharesAndPreFundedWarrants
27890000
aplt Proceeds From Issuance Of Shares And Pre Funded Warrants
ProceedsFromIssuanceOfSharesAndPreFundedWarrants
27899000
aplt Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
1546000
aplt Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
3105000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
928000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1408000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28529000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29596000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18959000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1840000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16657000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53888000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35616000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55728000
aplt Initial Measurement Of Warrant Liability
InitialMeasurementOfWarrantLiability
21835000
aplt Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
1417000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-51000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
113000
aplt Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
440000
aplt Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
96000
us-gaap Profit Loss
ProfitLoss
-39700000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-388500000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35600000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the Company's ability to continue as a going concern as of the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing the financial statements, management used estimates in the following areas, among others: prepaid and accrued expenses; warrant liability valuation; stock-based compensation expense; and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern.<span style="background:#ffffff;"> </span>Actual results could differ from those estimates.</p>
CY2022Q4 aplt Clinical Holdback
ClinicalHoldback
464000
aplt Clinical Holdback Retained
ClinicalHoldbackRetained
158000
CY2023Q2 aplt Clinical Holdback
ClinicalHoldback
622000
CY2023Q2 aplt Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 aplt Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q2 aplt Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 aplt Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
13873000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
13923000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
13873000
CY2022Q4 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxRollingWithinOneYear
50000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
13923000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
13873000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
13923000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2023Q2 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
4547000
CY2022Q4 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
4272000
CY2023Q2 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
1343000
CY2022Q4 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
1131000
CY2023Q2 us-gaap Prepaid Rent
PrepaidRent
198000
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
99000
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
164000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
71000
CY2023Q2 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
132000
CY2022Q4 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
206000
CY2023Q2 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
262000
CY2022Q4 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
252000
CY2023Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
23000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
23000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
536000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
674000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7205000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6728000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4308000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q2 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
11091000
CY2022Q4 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
8877000
CY2023Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1240000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
622000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1124000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1218000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
894000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2301000
CY2023Q2 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
843000
CY2022Q4 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
896000
CY2023Q2 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
370000
CY2022Q4 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
361000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
461000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
481000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16023000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14756000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1843000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2231000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3898000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4900000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4874047
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.97
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20174
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
69043
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
8048
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.05
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4776782
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
685000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4224592
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
558000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
552190
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.05
aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P8Y
CY2023Q2 aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue
127000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
126000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
126000
us-gaap Operating Lease Cost
OperatingLeaseCost
252000
us-gaap Operating Lease Cost
OperatingLeaseCost
126000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
257000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
426000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
683000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
27000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
656000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29577000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29577000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25857000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25857000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79041695
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79041695
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26901069
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26901069
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39714000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-39714000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48978000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-48978000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67762501
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67762501
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26560185
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26560185
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84

Files In Submission

Name View Source Status
0001558370-23-014406-index-headers.html Edgar Link pending
0001558370-23-014406-index.html Edgar Link pending
0001558370-23-014406.txt Edgar Link pending
0001558370-23-014406-xbrl.zip Edgar Link pending
aplt-20230630.xsd Edgar Link pending
aplt-20230630x10q.htm Edgar Link pending
aplt-20230630xex31d1.htm Edgar Link pending
aplt-20230630xex31d2.htm Edgar Link pending
aplt-20230630xex32d1.htm Edgar Link pending
aplt-20230630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
aplt-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aplt-20230630x10q_htm.xml Edgar Link completed
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aplt-20230630_cal.xml Edgar Link unprocessable
aplt-20230630_lab.xml Edgar Link unprocessable
aplt-20230630_def.xml Edgar Link unprocessable